^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-15 superagonist

    Related drugs:
    Apply
    QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL (NCT03169790)
    Phase 1/2
    ImmunityBio, Inc.
    Withdrawn
    Last update posted :
    02/24/2025
    Initiation :
    12/01/2017
    Primary completion :
    01/01/2019
    Completion :
    12/23/2021
    CD20
    |
    CD20 positive
    |
    Avastin (bevacizumab) • Rituxan (rituximab) • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • oxaliplatin • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-061 • NK92-CD16-158V • cyclophosphamide intravenous
    Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (NCT05642195)
    Phase 1/2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    02/24/2025
    Initiation :
    02/27/2025
    Primary completion :
    12/30/2033
    Completion :
    12/30/2035
    PD-L1
    |
    PD-L1 expression
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant
    Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (NCT05419011)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    05/08/2023
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
    QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (NCT03228667)
    Phase 2
    ImmunityBio, Inc.
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    12/11/2018
    Primary completion :
    08/31/2029
    Completion :
    12/31/2030
    BRAF • ALK • MSI
    |
    PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • docetaxel • Bavencio (avelumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer (NCT04847466)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    12/14/2021
    Primary completion :
    01/31/2025
    Completion :
    12/31/2025
    PD-L1
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer (NCT06253494)
    Phase 1/2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    06/14/2024
    Initiation :
    05/14/2024
    Primary completion :
    12/31/2026
    Completion :
    12/31/2028
    HER-2
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Anktiva (nogapendekin alfa inbakicept-pmln)
    Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) (NCT03493945)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    05/01/2018
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    TMB • BRCA1 • BRCA2 • MSI • HRD
    |
    TMB-H • MSI-H/dMMR
    |
    bintrafusp alfa (M7824) • epacadostat (INCB024360) • Anktiva (nogapendekin alfa inbakicept-pmln)
    N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma (NCT06061809)
    Phase 2
    ImmunityBio, Inc.
    Not yet recruiting
    Last update posted :
    05/29/2024
    Initiation :
    07/17/2024
    Primary completion :
    12/31/2029
    Completion :
    12/31/2030
    IL6 • TNFA
    |
    Avastin (bevacizumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (Lung-MAP Non-Match Sub-Study) (NCT05096663)
    Phase 2/3
    SWOG Cancer Research Network
    Active, not recruiting
    Last update posted :
    05/03/2024
    Initiation :
    03/15/2022
    Primary completion :
    02/01/2027
    Completion :
    12/01/2027
    EGFR • BRAF • ALK • ROS1 • NTRK
    |
    BRAF mutation • ALK fusion • ROS1 fusion • MET mutation • NTRK fusion
    |
    Keytruda (pembrolizumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln) • Hemady (dexamethasone tablets) • Pemfexy (pemetrexed)
    N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer (NCT05445882)
    Phase 2
    National Cancer Institute (NCI)
    Withdrawn
    Last update posted :
    04/02/2024
    Initiation :
    04/01/2024
    Primary completion :
    04/01/2024
    Completion :
    04/01/2024
    CD4
    |
    bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln)
    QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC. (QUILT2023) (NCT03520686)
    Phase 3
    ImmunityBio, Inc.
    Active, not recruiting
    Last update posted :
    02/07/2024
    Initiation :
    05/18/2018
    Primary completion :
    10/01/2025
    Completion :
    04/01/2026
    EGFR • PD-L1 • BRAF • ALK • ROS1 • NTRK
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln)
    ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer (NCT02523469)
    Phase 1/2
    Medical University of South Carolina
    Completed
    Last update posted :
    03/07/2023
    Initiation :
    01/08/2016
    Primary completion :
    02/24/2023
    Completion :
    02/24/2023
    ALK
    |
    EGFR mutation • ALK mutation
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • Anktiva (nogapendekin alfa inbakicept-pmln)
    Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 (NCT02890758)
    Phase 1
    Brenda Cooper, MD
    Completed
    Last update posted :
    02/20/2023
    Initiation :
    05/22/2018
    Primary completion :
    06/01/2021
    Completion :
    02/17/2023
    ABL1 • BCR • NCAM1
    |
    NCAM1 positive
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN) (NCT05007769)
    Phase 2
    Washington University School of Medicine
    Withdrawn
    Last update posted :
    11/05/2021
    Initiation :
    10/31/2021
    Primary completion :
    04/30/2024
    Completion :
    04/30/2026
    EGFR • PD-L1 • ALK • ROS1
    |
    EGFR mutation • ALK rearrangement • ROS1 rearrangement
    |
    Tecentriq (atezolizumab) • Cyramza (ramucirumab) • Anktiva (nogapendekin alfa inbakicept-pmln)
    A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors (NCT01946789)
    Phase 1
    Altor BioScience
    Completed
    Last update posted :
    04/17/2019
    Initiation :
    05/01/2014
    Primary completion :
    08/01/2017
    Completion :
    12/01/2017
    EGFR • BRAF • ALK
    |
    EGFR mutation • BRAF mutation • ALK rearrangement
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML (NCT03365661)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Withdrawn
    Last update posted :
    11/09/2018
    Initiation :
    10/30/2018
    Primary completion :
    01/01/2023
    Completion :
    01/01/2023
    TP53 • FLT3 • KIT • DNMT3A • RUNX1 • ASXL1 • HLA-DRB1 • HLA-B • HLA-C
    |
    TP53 mutation • FLT3-ITD mutation • FLT3 mutation • KIT mutation • DNMT3A mutation • ASXL1 mutation
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma (NCT02099539)
    Phase 1/2
    Altor BioScience
    Unknown status
    Last update posted :
    01/23/2018
    Initiation :
    10/01/2014
    Primary completion :
    11/01/2017
    Completion :
    10/01/2020
    IFNG • IL6 • TNFA • IL2 • IL10
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)